Niox Mino - Shed new light on airway inflammation and asthma managementNiox Mino - Shed new light on airway inflammation and asthma management
Managing asthma in the dark?Managing asthma in the dark?

Control airway inflammation, control asthma

While allergic airway inflammation is known to be the major underlying cause of asthma, there are few methods of measuring it. Evaluating airway inflammation using induced sputum or airway biopsy is expensive, invasive, time consuming, and often not readily available.

Now, there's NIOX MINO®—the first medical device designed to measure airway inflammation at the point of care.

Patients with allergic airway inflammation generally have higher than normal levels of nitric oxide (NO) in their exhaled breath.1 By measuring the concentration of NO in an exhaled breath (fractional exhaled nitric oxide or FeNO), clinicians can evaluate allergic airway inflammation in patients with underlying asthma.

NIOX MINO® offers

Reasons to obtain a FeNO measurement

Assist in diagnosis1

  • Diagnose eosinophilic airway inflammation
  • Support the diagnosis of asthma when objective evidence is lacking
  • Help determine when respiratory symptoms are not due to asthma
  • Determine whether uncontrolled allergic airway inflammation is contributing to poor asthma control

Aid in treatment

  • Determine the likelihood of steroid responsiveness1
  • Guide stepwise changes in anti-inflammatory medication (step-down dosing, step-up dosing, or discontinuation)1
    • The National Asthma Education and Prevention Program's Expert Panel Report 3 (NAEPP EPR-3) recommends a stepwise approach for managing asthma2

Assist in monitoring control and adherence1

  • Establish baseline FeNO level during a period of clinical stability, which can be subsequently monitored
  • Help determine whether patients are adhering to prescribed corticosteroid treatment

References: 1. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FeNO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615. 2. National Asthma Education and Prevention Program; National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Published August 28, 2007. Accessed September 13, 2011. 3. Barnett SBL, Nurmagambetov TA. Cost of asthma in the United States: 2002-2007. J Allergy Clin Immunol. 2011;127:145-152.

It has been estimated
that the total cost
of asthma to society
in the United States
is approximately $56 billion
annually.3

FeNO TESTS
ARE REIMBURSABLE:
CPT 95012
Confirm
No
Yes
Confirm
No
Yes